Audit: QRS - Binaural Beats for Health & Longevity
Audit conducted on 31/08/2026 03:30 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 84 |
| Failed | 0 |
| N/A | 9 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Spot-checked every populated span against the ER: protocol values (ER 331-339), time-to-effect (ER 388, 171), benefit and risk tier headings (ER 155-223, 249-277), gate items (ER 295-311), all 7 monitoring rows (ER 422-428) and all 5 qualitative markers (ER 432-436) are literally supported. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | ER carries no empty-state or hedging phrasing that the QRS restates; the ER’s own cautious framing sits in tier assignment, which the QRS mirrors. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | No tier promoted or demoted; contraindication thresholds (>25 dB at 4 kHz, >20 dB ear-to-ear gap, 200-400 Hz carrier) carried unchanged. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Benefit-Modifying and Risk-Modifying Factors (ER 228-236, 282-290) are not surfaced in the gates; Contraindications come only from ER 305-311 and Key Interactions only from ER 295-303. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, NCT identifiers, expert names, study citations or brand names appear anywhere in the QRS; instrument names (Pittsburgh Sleep Quality Index, State-Trait Anxiety Inventory) are ER table entries. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions introduced. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Matches the ER’s measured, non-promotional register. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Expert, objective and data-driven; the Protocol panel and Monitoring targets give the reader something actionable without overselling. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | No prescriptive verbs; content is stated, not directed. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | Monitoring targets and gates are presented as evidence-derived reference values, matching the ER framing. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No ‘recommend’, ‘advise’, ‘should’, ‘consider’ or ‘ensure’ in the document’s own voice; the only ‘must’ (line 578) is verbatim ER text inside a contraindication. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person address anywhere in the file. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Plain language throughout; the technical terms retained (pure-tone audiometry, RMSSD, dB(A)) are the ER’s own biomarker names and are each preceded by a plain-language descriptor. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Highly compact: ER tier headings reduced to semicolon-joined phrases, mitigations and mechanistic rationale stripped from the gates. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed: no ‘you’ / ‘your’ tokens. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Framing assumes a proactive reader who will run a baseline audiogram and re-score questionnaires at 4 and 12 weeks. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Protocol asks for daily 15-30 minute sessions, over-ear headphones and periodic audiometry. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Not written for a general audience; assumes willingness to track PSQI, STAI and RMSSD. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | Risk weighting reflects this audience: cumulative headphone sound exposure is elevated to the leading risk precisely because daily long-term use is assumed. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | No occurrence of ‘anti-aging’. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | Formal terminology in the document’s own voice (‘anaesthetic’, ‘sedative’, ‘analgesic requirement’, ‘adverse’); the single colloquial term ‘painkiller’ sits in [at_a_glance], is lifted verbatim from the ER Conclusion (ER 460), and is required there by item 7.4’s plain-language rule. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fixed headings verified against [qrs_template]: ‘Protocol’, ‘Time to effect’, ‘Benefits’, ‘Risk & Side Effects’, ‘Monitoring’, ‘Qualitative Assessment’, ‘Contraindications’, ‘Key Interactions’, tier labels High/Medium/Low/Speculative, and Marker/Target/Why. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 34 named template spans present, plus the repeatable marker_#name/target/why (7 instances) and qualitative_item# (5 instances). |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Byte-for-byte diff of lines 1-410 of the template against the QRS head/CSS shows changes only inside the metadata comment and the |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section is empty and the ER uses no empty-state phrasing (‘Not formally studied’, ‘None documented…’) anywhere; the ER’s Risks/High subsection carries prose (ER 245) and is governed by item 13.5 instead. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol cell labels reuse the ER bold labels verbatim (‘Standard session’, ‘Anxiety and pain protocol’, ‘Sleep protocol’, ER 331-337); all five Key Interaction labels reproduce the ER bold labels including their drug lists (ER 295-303). |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | No label paraphrased, abbreviated or invented. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | Unicode scan for emoji ranges returns nothing; the ER’s tier emoji and the six ‘Conflicted’ warning markers are correctly absent. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is condensed rather than extended: the ER’s 18 Protocol bullets reduce to 3 cells, the 7-row monitoring table drops the ER’s entire Context/Notes column, and the ER’s per-benefit Magnitude paragraphs are omitted entirely. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | The metadata comment opens at line 2, immediately after <!doctype html>, before <html> and any other comment. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | YAML opens at line 3 and closes at line 13; the preceding label text on line 2 is outside the delimiters. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment closed at line 14; none of its values are echoed by a visible element. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | All values trimmed; only duration: “00:03” is quoted, correctly, because it contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | er_filename: binaural_beats_2026-0831-0002_Opus_ER.md |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | qrs_prompt_version: 26.7.02, matching the version badge at the head of QRS.md. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | qrs_creation_date: 2026-0831-0328, correct YYYY-MMDD-HHMM form. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | qrs_creator_ai_nickname: Opus |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | Single word, no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | qrs_creator_ai_fullname: Opus 5 |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | Nickname plus version number only, no trailing qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | qrs_filename: binaural_beats_2026-0831-0002_Opus_QRS.html, matching the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified; no stray whitespace or unnecessary quoting on any of the nine keys. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | [header_topic] = ‘Binaural Beats for Health & Longevity’, identical to canonical_topic, entity-encoded. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | 08/31/2026, correctly derived from qrs_creation_date 2026-0831-0328. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | ‘Opus 5’, matching qrs_creator_ai_fullname. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header carries only the title and the template’s fixed subline; no badge, version stamp, alternate-names line or audit date. The ER’s ‘Also known as’ list (ER 30) is correctly not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Distils the ER Conclusion (ER 460-464) in decision order: what it is, cost, strongest finding, weaker findings, principal risk. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 59 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each of the six assertions maps to a distinct ER passage: mechanism/cost (ER 460 sentence 1 and ER 398), procedural anxiety and pain plus drug sparing (ER 460), sleep in poor sleepers (ER 460), memory and attention (ER 460), headphone sound exposure (ER 464). |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms and no specialist classifications; ‘binaural beat’, ‘entrainment’, ‘EEG’, ‘perioperative’ and ‘analgesic’ are all avoided in favour of plain equivalents (‘a pulsing beat the brain builds itself’, ‘painkiller’). |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial names, years, sample sizes or p-values. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No SMDs, confidence intervals, effect sizes or statistics; ‘modestly’, ‘small and inconsistent’ are qualitative. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All five items trace to the ER’s ‘Populations who should avoid Binaural Beats’ list (ER 305-311) inside Key Interactions & Contraindications. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All five ER avoid-populations are represented, none added. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Five <li> elements inside the [stop_items] span (QRS 571-581). |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Every trailing em-dash and comma clause of rationale is stripped: ‘rhythmic sensory drive is the shared provoking mechanism’, ‘adds to an already reduced reserve’ and ‘in whom the beat cannot be constructed at all’ are all removed. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Threshold and severity qualifiers preserved: ‘that is not fully controlled’, ‘more than 25 dB at 4 kHz’, ‘severe, distress-level’, ‘200-400 Hz’, ‘above 20 dB’, ‘for the duration of a session’. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s contraindication bullets contain no ranking notation inside parentheses. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | Section is populated, and the ER does name five populations that should avoid the intervention, so the emptiness condition is correctly not invoked. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not left empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All five items trace to the ER bullets at 295-303. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All five ER interaction bullets carried; none duplicates a contraindication. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Five <li> elements inside the [caution_items] span (QRS 589-614). |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Reduced to the ER’s verdict clause only; every ‘Mitigation:’ sentence and supporting rationale (e.g. ‘Randomized data show beats reduce the induction dose needed’) is stripped. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | All four parenthetical drug and modality lists preserved in full: (propofol, remimazolam, midazolam); (zolpidem, zopiclone, trazodone); (diphenhydramine, doxylamine); (melatonin, valerian, L-Theanine, magnesium glycinate, glycine); (cognitive behavioural therapy for insomnia, meditation, breathwork, neurofeedback). |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s interaction bullets contain no ranking notation inside parentheses. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | Section is populated, and the ER does identify additive interactions, so the emptiness condition is correctly not invoked. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not left empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells derive from the ER Therapeutic Protocol section (ER 331-339). |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | The three sets carry the ER’s three named dosing protocols: the Standard session (with the ER’s ‘Timing before the task’ bullet folded into its sub-line), the Anxiety and pain protocol, and the Sleep protocol. The Focus protocol is appended to action_3_sub under its own verbatim ER label, which is a legitimate one-page condensation rather than a substitution. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER names more than three actionable implementation aspects; all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine sub-fields populated with ER-derived content; values carry the ER’s numbers (15-30 min once daily; beat 1-10 Hz on a 200-400 Hz carrier 20-30 min pre-procedure; beat 1-8 Hz for 20-30 min at bedtime). |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Three aspects: within-session onset for anxiety and pain (ER 388), 20-30 min pre-induction exposure for anaesthetic sparing (ER 171), and at least two weeks of nightly use for sleep (ER 388). |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Ordered High -> Medium -> Low, matching the ER benefit tiers of the related outcomes (procedural anxiety and pain = High; anaesthetic and sedative requirement = Medium; sleep quality = Low). |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct time-to-effect aspects exist in the ER; all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine sub-fields populated and ER-supported; time_1_sub, time_2_sub and time_3_sub each paraphrase a single ER sentence without adding figures. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER does provide time-to-effect information (ER 388), so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All four tiers map to the ER Expected Benefits headings (ER 153-223). |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present and populated. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Every item is the ER heading reduced to sentence case; all Magnitude paragraphs, effect sizes, trial descriptions and the six ‘Conflicted’ markers are dropped. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content carried; the ER’s inline glosses and pooled figures are absent. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four benefit tiers contain at least one ER item (High 2, Medium 2, Low 6, Speculative 1), so no span needed hiding. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All tiers map to the ER Potential Risks & Side Effects headings (ER 243-277). |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each item is the ER heading in sentence case with no rationale, prevalence figure or study detail. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content carried; the ER’s pooled prevalence figures and population attributable fraction are absent. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | The ER’s High tier holds no risk item (ER 245), and [risks_high] is correctly emptied and set to style=”display: none” at QRS 626 rather than filled with empty-state text. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Derived from the ER Monitoring Protocol & Defining Success section (ER 414-428). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All 7 ER biomarker rows are present in the same order, with Optimal Functional Range mapped to Target and Why Measure It? mapped to Why; the RMSSD target is faithfully condensed from the ER’s two-clause entry. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Populated from ER 416-418: baseline before starting, questionnaires re-scored at 4 and 12 weeks, hearing test every 12-24 months or sooner if tinnitus or muffled hearing appears. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Derived from the ER’s ‘Qualitative markers worth tracking alongside the numbers’ list (ER 430-436). |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All 5 ER qualitative markers listed, verbatim and in ER order. |
Issues 31/08/2026 03:30
Pass rate 100.00%. No issues found.